Navigation Links
Second Quarter Health Care M&A Strongest In Years According To New Report From Irving Levin Associates, Inc.
Date:7/9/2008

20 15 33% 15 33%

Technology Subtotal 155 113 37% 131 18%

Grand Total 265 223 19% 252 5%

*Preliminary figures

These results point to a resurgence of interest in health care M&A despite a lackluster start at the beginning of the year. "After a lethargic first quarter, both deal and dollar volume in the health care M&A market surged in the second," stated Sanford Steever, Ph.D., editor of The Health Care M&A Report. "Given the relative absence of financial buyers from the market, a greater number of strategic buyers now feel more confident in entering the market," added Mr. Steever.

The Health Care industry continues to attract more interest from potential deal makers than other sectors of the economy. "The combination of health care and technology is proving irresistible for investors and operators looking to enter the M&A market," commented Stephen M. Monroe, managing editor at Irving Levin Associates. "While sectors such as Medical Devices and Biotechnology are obvious magnets for M&A dollars, so too are technologically-oriented services sectors such as Infusion Therapy and Contract Research Organizations."

"Though not completely insulated from the surrounding economy and its influence, the health care M&A market appears to run on an internal logic of its own and to have access to sufficient capital to make it happen," Mr. Steever summarized. "Deals in health care technology will likely drive the market for the remainder of the year."

For more information on The Health Care M&A Report, or for a subscription to any Irving Levin publications, call 800-248-1668. Irving Levin Associates, Inc., established in 1948, has headquarters in Norwalk, CT and is online at http://www.levinassociates.com. This privately held corporation publishes research reports and newsletters, and ma
'/>"/>

SOURCE Irving Levin Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Response Genetics Reports Second Quarter 2007 Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Transgenomic, Inc. Reports Second Quarter 2007 Results
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... DIEGO, Dec. 11 Ambit Biosciences Corporation announced ... Texas M. D. Anderson Cancer Center of the first ... Monotherapy E fficacy) Phase 2 pivotal ... leukemia (AML). AC220 is a novel, orally available, ... designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... Calif., Dec. 11 Marrone Bio Innovations ... executive management team. Mr. Chris Hildreth joined MBI ... is responsible for expanding all commercial aspects of ... functions. Dr. Kin Sing (Ray) Lam joined MBI ... the company,s development efforts in scaling its broad ...
(Date:12/11/2009)... Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, ... announced the appointment of Dr. Alan Warrander to ... and Business Development. ,, "Dr. Warrander will be ... strategy for REOLYSIN(R)," said Dr. Brad Thompson, President ... on the design of a Phase 3 trial ...
(Date:12/10/2009)... Dec. 10 Dendreon Corporation (Nasdaq: DNDN ... public offering of 15,000,000 shares of its common stock ... share. Dendreon also granted to the underwriters a ... shares of common stock to cover overallotments, if any. ... 15, 2009, subject to customary closing conditions. ,, J. ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3
... this year,s,Venture Forum to the life sciences industry, Larta ... developing and producing the 2008,Life Sciences Venture Forum, which ... life sciences companies from the U.S. and,around the globe. ... on,May 30, 2008, at the Santa Clara Convention Center ...
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX:ONY) announced ... studies of PX-12 and preclinical studies of,PX-866 will ... American Association,for Cancer Research (AACR) in San Diego ... a Phase 1 clinical trial of PX-478,in patients ...
... CHICAGO, April 10 Advanced Life Sciences,Holdings, Inc. ... on a productive,meeting with the U.S. Food and ... New Drug Application (NDA) in the third quarter ... to treat mild-to-moderate,community acquired pneumonia (CAP)., (Logo: ...
Other Biology Technology:Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 2Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 3Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 3Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin 2Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin 3
(Date:12/11/2009)... about the deep ocean,s temperature variability and circulation system ... The deep ocean is affected more by surface warming ... accurate predictions of factors such as sea level rise ... have also been found to result in a more ... a faster transport of large quantities of warm water, ...
(Date:12/11/2009)... been limited by the seasons, particularly in ... short. Thanks to researchers and fruit breeders, ... offer growers the ability to produce fruit ... both producers and consumers. Fresh examples are ... which bear fruit on current-season canes, or ...
(Date:12/11/2009)... German . , Halle/Saale. With ... than extinctions, plant communities of many European regions ... occurring more frequently, whereas rare species are becoming ... that are becoming increasingly similar, but also the ... to a loss of uniqueness among European floras, ...
Breaking Biology News(10 mins):New discoveries could improve climate projections 2New management methods extend blackberry season 2Europe's flora is becoming impoverished 2Europe's flora is becoming impoverished 3Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug 62443 1Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug 62443 22009 winner of the Manpei Suzuki international prize for diabetes research announced 10958 1ILS Technology and Customer ASML Recipients of Industry Recognition Awards 62442 1ILS Technology and Customer ASML Recipients of Industry Recognition Awards 62442 2
... cause of death in Europe and early diagnosis is ... and electrical activity in real time using an electrocardiogram ... to the nature of a problem. Some cardiac conditions ... requires them to be away from their everyday environment ...
... from two Michigan universities have joined technical and ... technology and computer algorithms to work in the ... is that a new approach to analyzing sleep ... controls. , Joseph W. Burns, a research ...
... given quercetin, a naturally occurring substance found in fruits ... according to a study published by The American Physiological ... the susceptibility of mice to the flu, but quercetin ... chemical relative of resveratrol, is present in a variety ...
Other Biology News:A home early warning system for cardiac patients 2What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3Substance found in fruits and vegetables reduces likelihood of the flu 2Substance found in fruits and vegetables reduces likelihood of the flu 3
... An immuncapture enzyme-activity assay based on measurenment ... on monoclonal antibody coated microtiter plate. The ... standards, samples or controls, 2nd enzyme ... assay is intended for the determination of ...
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... HT is available as a ...
... Pseudomonas atlantica Description: Beta-Agarase is useful ... from low-melting-temperature agarose. Beta-Agarase digests the ... User Friendly Properties: Heat Inactivation: 65C, ... Optimum pH: 6.5 Purity: Tested for ...
iEMS Thermal Microplate Holder...
Biology Products: